Eltrombopag

CAS : 496775-61-2

Ref. 3D-FE22658

Informations sur le produit

• Nom: Eltrombopag
• Synonymes: 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxyl ic acidSB 497115, 3'-[2-[(2Z)-1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid, 3′-[(2Z)-2-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid, Sb 497115, [1,1′-Biphenyl]-3-carboxylic acid, 3′-[(2Z)-2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2′-hydroxy-, [1,1′-Biphenyl]-3-carboxylic acid, 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-

Description

Agonist of thrombopoietin receptor TpoR, which triggers activation of the JAK2/STAT5 signalling pathway. Eltrombopag is indicated in individuals with thrombocytopenia since it leads to increased proliferation of megakaryocyte progenitor cells and increased production of platelets. Eltrombopag also enhances expansion of human umbilical cord blood hematopoietic stem/primitive progenitor cells and promotes hematopoiesis.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 442.47 g/mol
• Formule: C₂₅H₂₂N₄O₄
• Degré de pureté: Min. 98 Area-%
• Couleur/Forme: Powder